Bayer Promem
Executive Summary
FDA's Peripheral & Central Nervous System Drugs Advisory Committee will review metrifonate (NDA 20-914) for treatment of mild to moderate dementia of the Alzheimer's type on Jan. 27. The following day, the committee will review Immunex' Novantrone (mitoxantrone, NDA 21-120) for treatment of secondary progressive multiple sclerosis ("The Pink Sheet" Dec. 13, 1999, p. 22). The meeting begins at 8:00 a.m. at the Hilton in Gaithersburg, Md. on both days